Proceeds from the financing round will be used to extend the company's Precision-FirstTM platform and expand its therapeutic pipeline to include programs for chronic immune-mediated diseases. In addition, proceeds will be used to advance Antithrombin III, Endpoint Health's first precision therapy, to a Phase II clinical trial for the treatment of sepsis. The company expects to submit its Investigational New Drug (IND) application and Investigational Device Exemption (IDE) to the US Food and Drug Administration (FDA) for its Antithrombin III program later this year.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

401 Lambert Ave
Palo Alto, CA 94306
USA

Phone

(650) 561-4401

Website

www.endpointhealth.com

Email Address

[email protected]

Overview

We're building a new kind of biopharma. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jason Springs

Chief Operating Officer

Leonardo Teixeira

Chief Scientific Officer

Diego Rey

Browse more venture capital transactions:

Prev: 6/2/2022: Felux venture capital transaction
Next: 6/2/2022: Incognia venture capital transaction

Share this article

Where The Data Comes From

We do our best to record tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary